Prospects for specific immunotherapy in myasthenia gravis.
Myasthenia gravis is an autoimmune disease resulting from a breakdown in T and B cell tolerance to acetylcholine receptor (AChR). Autoantibodies to AChR mediate the disease. Recent advances in experimental immunotherapy of autoimmune disease provide several possibilities for specific intervention in this well-characterized condition.
Department of Genetics, Stanford University School of Medicine, California 94305.
L
L
Steinman
R
R
Mantegazza
D006801:Humans; D007167:Immunotherapy; D008285:Major Histocompatibility Complex; D009157:Myasthenia Gravis / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D011950:Receptors, Cholinergic / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D013950:Thymus Gland / Q000276:immunology
D011950:Receptors, Cholinergic